first
line
immun
defens
pathogen
guarante
recognit
pathogen
associ
molecular
pattern
pamp
pattern
recognit
receptor
prr
famili
prr
includ
secret
membranebound
cytosol
prr
pathogen
organ
use
sophist
strategi
modul
prr
recognit
control
downstream
signal
accordingli
human
enteropathogen
shigella
exploit
differ
mechan
hijack
innat
immun
respons
shigella
genu
includ
serogroup
boydi
dysenteria
flexneri
sonnei
flexneri
main
serogroup
circul
industri
develop
countri
respect
studi
center
invas
process
shigella
vitro
vivo
carri
flexneri
shigella
penetr
epitheli
cell
seri
effector
secret
via
type
secret
system
encod
larg
virul
plasmid
common
shigella
serogroup
insid
colon
mucosa
shigella
either
fuel
dampen
inflammatori
respons
depend
step
invas
process
epitheli
cell
shigella
multipli
freeli
within
cytoplasm
cytosol
prr
recogn
cellwal
peptidoglycan
pgn
activ
lead
product
attract
neutrophil
requir
clearanc
shigella
also
particip
destruct
epitheli
barrier
within
epitheli
cell
flexneri
chang
lipopolysaccharid
lp
structur
highli
inflammatori
hexaacyl
lipid
form
less
inflammatori
tetra
triacyl
lipid
variant
lowinflammatori
lp
poorli
recogn
prr
tolllikereceptor
make
macrophag
neutrophil
less
abl
control
infect
furthermor
b
lymphocyt
shigella
induc
apoptot
death
mechan
mediat
independ
cell
invas
immun
evas
strategi
involv
prr
present
surfac
mani
cell
popul
suggest
extracellular
step
could
critic
success
infect
gain
insight
poorli
explor
aspect
shigella
pathogenesi
analyz
potenti
role
humor
prr
focus
possibl
involv
pentraxin
serv
paradigm
humor
innat
immun
key
element
humor
arm
innat
immun
downstream
complementari
cellular
recognit
activ
pentraxin
evolutionarili
highli
conserv
superfamili
protein
prototyp
long
pentraxin
short
pentraxin
includ
creactiv
protein
crp
serum
amyloid
p
compon
sap
acutephas
protein
man
mous
respect
rapidli
produc
releas
sever
cell
type
eg
mononuclear
phagocyt
dendrit
cell
dc
neutrophil
respons
primari
inflammatori
signal
eg
tlr
engag
bind
select
microorgan
includ
aspergillu
fumigatu
pseudomona
aeruginosa
uropathogen
escherichia
coli
upec
also
promot
complement
activ
therebi
facilit
pathogen
recognit
phagocyt
featur
prompt
us
investig
whether
could
play
role
shigella
pathogenesi
extent
prr
releas
upon
shigella
infect
find
highlight
new
player
shigella
crosstalk
infect
tissu
provid
novel
insight
mechan
shigella
control
product
humor
prr
firstli
address
question
whether
could
opson
shigella
report
fumigatu
salmonella
typhimurium
p
aeruginosa
neisseria
meningid
uropathogen
e
coli
upec
observ
opson
wild
type
flexneri
strain
fig
plasmidless
noninvas
variant
though
lesser
extent
compar
p
aeruginosa
strain
use
posit
control
epitheli
cell
invas
macrophag
death
hallmark
shigella
pathogenesi
investig
whether
bind
could
affect
epithelialcel
penetr
shigella
incub
differ
concentr
recombin
prior
infect
hela
cell
treat
bovin
serum
albumin
bsa
rabbit
polyclon
antibodi
rais
ipad
involv
bacteri
intern
use
parallel
shown
fig
opson
concentr
significantli
decreas
number
intracellular
bacteria
h
h
postinfect
pi
p
vs
plu
bsa
level
like
induc
antiipad
antibodi
human
peripher
blood
monocytesderiv
macrophag
mom
opson
recombin
concentr
determin
signific
improv
bacteri
phagocytosi
concentr
fig
fig
p
vs
plu
bsa
likewis
rate
mom
cell
death
measur
lactat
dehydrogenas
ldh
releas
fig
fig
improv
opson
also
shown
antiipad
antibodi
howev
cell
death
rate
follow
trend
sinc
increas
concentr
p
plu
bsa
fig
also
involv
complement
cascad
activ
regul
scant
date
literatur
shigella
sensit
bactericid
activ
serum
set
bactericid
serum
assay
flexneri
preliminari
experi
use
differ
serum
concentr
min
found
sensit
concentr
pool
normal
human
serum
nh
exposur
nh
kill
around
bacteria
fig
addit
low
concentr
bactericid
serum
assay
serum
significantli
increas
bacteri
death
rate
bacteria
fig
conclus
bacteria
partial
impair
abil
invad
epitheli
cell
better
intern
macrophag
shown
antibodybound
bacteria
low
dose
increas
bactericid
activ
serumcompl
therefor
pass
analyz
possibl
contribut
vivo
infect
sever
report
describ
therapeut
effect
recombin
model
aspergillosi
p
aeruginosa
acut
chronic
lung
infect
acut
respiratori
syndrom
influenza
viru
lung
infect
mice
natur
resist
shigella
oral
infect
therefor
altern
infect
model
develop
use
among
intranas
rout
infect
mice
extens
use
valid
studi
shigella
virul
analyz
vaccin
candid
intranas
infect
virul
shigella
mice
develop
dramat
pneumonia
die
within
day
line
issu
investig
whether
treat
mice
recombin
could
affect
outcom
intranas
infect
shown
pathogen
base
previous
perform
pharmacokinet
analys
therapeut
approach
murin
model
lung
infect
fumigatu
p
aeruginosa
establish
treatment
schedul
daili
intraperiton
ip
inject
recombin
human
mgkg
vehicl
start
day
inoculum
x
coloni
form
unit
cfu
correspond
dose
treatment
carri
hour
three
inject
follow
experiment
plan
monitor
anim
survivaldeath
three
independ
experi
week
expect
hour
mice
infect
die
die
contrast
anim
infect
treat
surviv
even
treatment
stop
p
twotail
mantelcox
test
fig
h
postchalleng
bacteri
load
lung
anim
cfu
per
lung
previous
publish
wherea
treat
anim
number
cfu
per
lung
cfu
significantli
p
reduc
respect
infect
untreat
anim
fig
local
level
proinflammatori
cytokin
chemokin
measur
bal
broncho
alveolar
lavag
fig
lung
homogen
fig
chose
chemokinescytokin
previous
shown
influenc
treatment
andor
involv
shigella
infect
rant
valu
similar
bal
lung
homogen
untreat
infect
anim
drastic
decreas
homogen
bal
mice
compar
infecteduntr
mice
p
twotail
mannwhitney
test
furthermor
quantifi
level
sera
fig
lung
homogen
fig
bal
fig
lung
homogen
anim
level
lower
infect
uninfect
mice
p
twotail
mannwhitney
test
likewis
bal
sera
level
significantli
p
twotail
mannwhitney
test
reduc
anim
respect
treat
macroscop
examin
fig
top
lung
infect
mice
enlarg
rubberi
consist
edemat
duski
red
color
due
sever
hyperemia
lung
infect
anim
macroscop
like
control
appear
aerat
pinkish
spongi
lung
mice
hematoxylineosin
stain
show
acut
pneumonia
sever
bronchoalveol
alveolar
edema
mani
damag
area
parenchyma
pulmonari
phlogosi
character
sever
diffus
neutrophil
infiltr
peribronchi
intralumin
interstiti
area
alveoli
fig
contrast
infect
mice
lung
conserv
physiolog
architectur
moder
inflamm
aerat
parenchyma
airway
low
scatter
neutrophil
exud
fig
histopatolog
score
tabl
confirm
observ
immunohistochem
stain
tissu
untreat
mice
fig
reveal
diffus
product
due
involv
bronchial
mucosa
cell
rare
interspers
neutrophil
strong
observ
lung
section
infect
mice
fig
uninfect
mice
bare
detect
scatter
pmn
physiolog
associ
bronchial
mucu
balt
fig
oppos
protect
effect
recombin
model
p
aeruginosa
fumigatu
lung
infect
mice
show
increas
mortal
lung
colon
likewis
mice
suscept
wild
type
influenza
viru
upec
infect
henc
assess
whether
defici
could
affect
virul
shigella
aim
mice
infect
via
intranas
rout
anim
monitor
week
found
mice
challeng
show
acceler
death
respect
wild
type
mice
p
twotail
mantelcox
test
major
anim
die
hour
pi
fig
time
point
wild
type
infect
mice
die
bacteri
load
lung
infect
anim
around
ten
time
vs
p
twotail
mannwhitney
test
found
infect
wild
type
anim
fig
likewis
level
bal
fig
lung
homogen
fig
significantli
higher
p
twotail
mannwhitney
test
elicit
infect
wild
type
mice
conclus
find
suggest
involv
shigella
pathogenesi
nevertheless
genet
rescu
transgen
express
recombin
administr
mice
could
consolid
result
proceed
examin
whether
extent
shigella
infect
could
trigger
per
se
releas
dc
major
sourc
releas
follow
trigger
variou
inflammatori
cytokin
bacteri
pamp
bmdc
mice
infect
invas
strain
noninvas
isogen
strain
lack
virul
plasmid
bmdc
infect
shigella
multipl
infect
moi
product
monitor
parallel
h
postinfect
pi
induc
significantli
higher
releas
fig
releas
equival
strain
fig
test
invas
correl
releas
introduc
anoth
noninvas
strain
assay
lack
invasin
ipab
thu
noninvas
epitheli
cell
even
still
construct
machineri
releas
induc
similar
fig
confirm
trend
infect
protocol
bmdc
modifi
abrog
invas
phenotyp
releas
measur
first
bmdc
expos
invas
noninvas
strain
previous
kill
gentamicin
fig
bacteria
potenti
could
phagocyt
dc
howev
invas
abil
destroy
releas
chang
bmdc
infect
kill
contrast
valu
induc
kill
significantli
higher
record
live
prevent
cell
intern
bacteria
treat
cell
cytochalasin
disrupt
cytoskeleton
organ
contrast
previou
approach
invas
noninvas
bacteria
could
intern
cell
condit
valu
induc
compar
fig
two
differ
experiment
approach
aim
differ
prevent
invas
phenotyp
virul
shigella
howev
condit
intern
live
cell
inhibit
lead
signific
increas
releas
therefor
analyz
product
parallel
human
peripher
blood
modc
differ
releas
observ
invas
noninvas
shigella
strain
bmdc
also
record
modc
fig
trend
releas
similar
observ
fig
contrast
observ
bmdc
product
equal
induc
two
strain
result
indic
inhibit
cell
either
bacteria
kill
defici
virul
plasmid
host
cell
cytoskeleton
higher
releas
human
murin
dc
evalu
signal
pathway
involv
product
analyz
put
role
factor
involv
downstream
tlr
signal
trif
infect
bmdc
significantli
reduc
releas
respect
wildtyp
bmdc
fig
similar
trend
note
product
fig
absenc
trif
greatli
reduc
product
shown
fig
likewis
measur
drastic
reduc
total
abrog
trif
bmdc
fig
lp
uniqu
pamp
engag
trif
pathway
investig
whether
lp
could
trigger
releas
also
shown
upec
shigella
modifi
lp
composit
intracellular
resid
epitheli
cell
intracellular
bacteria
possess
hypoacyl
lipid
character
blend
lipid
form
tetra
triacyl
variant
preval
hexaacyl
isoform
main
compon
present
lp
grown
laboratori
media
mutant
carri
pentaacyl
tetraacyl
lipid
form
fulli
invas
purifi
lp
strain
show
low
inflammatori
potenti
accord
lipid
structur
check
whether
lp
composit
could
impact
product
dc
treat
three
shigella
lp
variant
extract
bacteria
grown
laboratori
medium
acellular
lp
purifi
intracellular
bacteria
intracellular
lp
lp
e
coli
lp
use
parallel
bmdc
stimul
ilp
lp
produc
lower
level
respect
alp
e
coli
lp
consist
degre
lipid
acyl
fig
releas
reflect
differ
lpss
fig
examin
whether
composit
lp
live
bacteria
could
affect
yield
use
invas
assay
howev
releas
similar
despit
differ
lipid
composit
fig
fig
modc
stimul
three
shigella
lp
form
alp
ilp
lp
follow
scheme
describ
bmdc
yield
drastic
decreas
ilp
lp
respect
alp
fig
releas
follow
trend
fig
contrast
result
bmdc
accord
lipid
composit
amount
infect
modc
lower
fig
fig
thu
addit
invas
lp
composit
play
pivot
role
trigger
releas
human
dc
effect
acyl
degre
lp
live
bacteria
evid
murin
dc
fig
line
differ
lipid
asensit
report
macrophag
sourc
infect
analyz
whether
shigella
could
promot
releas
macrophag
shown
dc
mous
bmdm
infect
differ
yield
like
observ
bmdc
fig
releas
follow
trend
releas
cytokin
similar
two
strain
fig
howev
report
shigellainfect
macrophag
poorli
respons
shigella
infect
absenc
adequ
prestimul
infect
lpsprime
bmdm
describ
previous
evalu
influenc
lp
modif
releas
bmdm
prime
alp
mainli
hexaacyl
ilp
mainli
tetraacyl
lp
mainli
pentaacyl
infect
moi
infect
bmdm
prime
ilp
lp
lpss
hypoacyl
releas
significantli
less
prime
alp
fig
amount
similar
lpss
alreadi
shown
fig
stimul
bmdm
without
infect
three
shigella
lp
ngml
h
yield
lower
ilp
lp
lpss
hypoacyl
alp
fig
fig
evalu
rel
role
structur
lp
live
bacteria
lp
prime
bmdm
prime
differ
lpss
infect
carri
pentaacyl
lp
instead
carri
hexaacyl
lp
releas
follow
trend
observ
consist
acyl
degre
lpss
use
prime
howev
trigger
significantli
lower
releas
compar
condit
accord
hypoacyl
degre
lp
fig
differ
maintain
signific
differ
induc
prime
variou
lpss
fig
examin
whether
mom
peripher
blood
monocytederiv
macrophag
respond
shigella
infect
lp
stimul
observ
bmdm
bmdc
modc
aim
mom
infect
either
stimul
differ
lp
product
evalu
infect
fig
yield
fig
significantli
higher
result
consist
seen
bmdm
bmdc
modc
likewis
induc
lowest
product
accord
lp
structur
also
observ
bmdm
modc
mom
stimul
four
form
lp
ilp
alp
e
coli
lp
ilp
lp
induc
lowest
product
fig
bmdm
fig
togeth
experi
suggest
lp
composit
major
trigger
product
macrophag
product
influenc
structur
lp
infect
bacteria
purifi
lp
use
stimul
prime
final
address
question
downstream
signal
lead
releas
bmdm
shown
bmdc
use
trif
bmdm
fig
describ
bmdc
surprisingli
releas
abrog
knockout
bmdm
indic
pathway
synergist
product
accord
publish
result
found
pathway
mainli
involv
releas
fig
contribut
trif
pathway
bmdm
valu
significantli
lower
wildtyp
cell
absenc
impair
releas
fig
result
highlight
differ
pathway
lead
releas
although
sonnei
main
serogroup
circul
highincom
countri
recent
year
sonnei
also
observ
prevail
flexneri
previous
low
incom
countri
socioeconom
condit
improv
evalu
whether
sonnei
could
like
flexneri
induc
product
bmdc
modc
bmdm
mom
infect
sonnei
fig
releas
induc
sonnei
similar
induc
cell
popul
likewis
similar
strain
condit
fig
involv
shigellosi
prompt
us
investig
level
plasma
shigellosi
patient
plasma
sampl
collect
patient
acut
stage
day
onset
cultureproven
sonnei
shigellosi
healthi
subject
level
measur
mean
level
significantli
higher
patient
group
ngml
compar
control
group
ngml
p
highest
level
patient
control
ngml
ngml
respect
fig
level
significantli
higher
within
day
diseas
onset
sampl
collect
later
posit
associ
sign
symptom
relat
sever
shigellosi
bodi
temperatur
number
wateri
stool
per
hour
bloodi
stool
tabl
among
acut
case
sonnei
shigellosi
whose
maxim
measur
bodi
temperatur
mean
level
much
higher
among
acut
patient
whose
maxim
measur
temperatur
equal
similar
result
found
regard
presenc
blood
stool
sign
sever
present
albeit
reach
borderlin
statist
signific
p
p
respect
role
humor
arm
innat
immun
poorli
explor
context
intracellular
bacteri
pathogen
like
shigella
unveil
phase
fluid
prm
could
play
decis
role
resolv
shigella
infect
treatment
recombin
human
rescu
anim
death
murin
model
pulmonari
shigellosi
oppos
protect
effect
recombin
infect
mice
show
defect
abil
clear
bacteria
acceler
kinet
death
infect
model
line
observ
p
aeruginosa
fumigatu
upec
therapeut
effect
alreadi
report
extracellular
pathogen
p
aeruginosa
fumigatu
streptococcu
sui
prm
influenc
pathogen
phagocytosi
opson
microorgan
reinforc
complement
activ
lung
infect
anim
bacteri
load
high
report
number
significantli
reduc
anim
vitro
opson
impair
shigella
intern
epitheli
cell
replic
nich
pathogen
likewis
bind
human
cytomegaloviru
inhibit
viralcel
fusion
intern
supposedli
crosslink
glycoprotein
viral
cellular
surfac
bind
shigella
might
inhibit
bacteriahost
cell
contact
interf
steric
machineri
therebi
affect
bacteri
micropinocytosi
antibodi
direct
shigella
surfac
structur
shown
prevent
epitheli
cell
intern
studi
promot
opsonophagocyt
activ
macrophag
light
opson
reminisc
vitro
properti
protect
antibodi
shigella
extern
structur
thu
contribut
shigella
erad
adapt
immun
respons
mount
featur
reveal
role
anteantibodi
shigella
infect
local
level
infect
extracellular
shigella
longer
protect
host
cell
cytoplasm
target
complement
system
easili
intern
macrophag
thu
improv
bacteri
clearanc
tissu
observ
lung
mice
inde
shigella
sensit
serum
bactericid
activ
studi
low
concentr
increas
kill
activ
complement
unsurpris
contribut
complement
activ
low
concentr
given
play
doubl
role
either
activ
three
complement
pathway
neg
regul
variou
mechan
therebi
limit
complementmedi
inflamm
moreov
architectur
lung
infect
anim
destroy
dramat
inflamm
mainli
character
massiv
neutrophil
infiltr
mice
high
level
chemokin
act
potent
neutrophil
chemoattract
contribut
lung
injuri
infect
mice
inflammatori
respons
seem
exacerb
product
significantli
higher
wild
type
anim
contrast
lung
infect
mice
low
level
associ
area
fill
neutrophil
exud
also
directli
contribut
local
regul
inflammatori
reaction
base
neutrophil
infiltr
bind
adhes
molecul
pselectin
inhibit
leukocyt
roll
endothelium
although
find
sound
encourag
definit
result
could
achiev
genet
rescu
transgen
express
infect
mice
altern
administr
recombin
anim
wild
type
mice
serum
level
ngml
h
infect
rang
observ
plasma
shigellosi
patient
patient
aspergillosi
likewis
level
bal
rang
record
bal
ngml
mice
infect
fumigatu
influenza
viru
pathogen
sensit
protect
effect
find
aris
question
whether
could
play
role
natur
infect
human
clinic
trial
dysenteria
still
invas
vaccin
increas
observ
plasma
vaccin
individu
suggest
invas
epitheli
layer
shigella
suffici
rise
amount
system
level
contrast
attenu
strain
like
confin
epitheli
layer
fulli
virul
shigella
break
integr
epitheli
barrier
penetr
mucosa
induc
sever
inflamm
character
huge
amount
cytokin
inflammatori
factor
act
signal
promot
releas
line
issu
plasma
patient
shigellosi
infect
sonnei
level
correl
posit
sever
symptom
particularli
high
temperatur
blood
stool
reliabl
paramet
sever
shigellosi
condit
like
sepsi
critic
infect
seem
shigella
invas
alon
poorli
promot
product
analyz
releas
vitro
upon
shigella
infect
epitheli
cell
macrophag
dc
neutrophil
contribut
shigellamedi
inflamm
describ
produc
vitro
intestin
cell
cell
releas
increas
mrna
express
upon
exposur
bacteria
bacteri
moieti
likewis
shigellainfect
cell
produc
detect
level
fig
moreov
bronchial
epitheli
cell
express
produc
upon
trigger
follow
bacteri
pamp
stimul
lp
could
suggest
natur
experiment
shigellosi
epitheli
cell
bare
produc
upon
initi
bacteri
contact
like
releas
inflammatori
signal
like
especi
present
upon
inflammatori
activ
neutrophil
releas
preform
content
lactoferrin
granul
lung
section
infect
anim
neutrophil
strongli
immunostain
neutrophil
recruit
inflammatori
mediat
could
constitut
main
sourc
upon
shigella
invas
vivo
condit
contrast
epitheli
cell
shigellainfect
macrophag
dc
produc
howev
virulentinvas
shigella
induc
lower
level
noninvasiveavirul
shigella
cell
suggest
phenotyp
associ
invas
play
major
role
control
product
lp
main
shigella
trigger
macrophag
dc
elicit
product
contrast
upecinfect
cell
secret
upon
activ
mediat
pathway
trif
particip
product
shigellainfect
macrophag
dc
involv
trif
pathway
evid
absenc
trif
abrog
massiv
reduc
releas
bmdm
bmdc
respect
role
product
alreadi
observ
context
tissu
repair
remodel
shigellainfect
bmdm
involv
product
therebi
suggest
downstream
signal
pathway
diverg
upon
activ
composit
lp
fine
modul
product
accord
degre
acyl
hypoacyl
lp
deriv
intracellular
shigella
stimul
reduc
releas
respect
hexaacyl
lp
extract
bacteria
grown
convent
condit
also
report
cytokin
product
impact
lp
composit
present
live
bacteria
yield
particularli
evid
human
cell
experiment
condit
lp
composit
tune
product
fine
product
result
strongli
link
product
lp
composit
also
differ
physiolog
patholog
context
conclus
local
level
shigella
infect
could
tip
balanc
toward
bacteri
erad
play
doubl
role
bacteri
side
help
reduc
epitheli
cell
invas
implement
macrophag
phagocytosi
favor
complement
activ
host
tissu
side
contribut
prevent
develop
destruct
inflamm
main
featur
shigellosi
immun
evas
behavior
favor
bacteri
surviv
prolifer
thu
allow
tissu
colon
initi
phase
diseas
suggest
could
potenti
contribut
erad
infect
target
poorli
explor
extracellular
phase
invas
process
consid
achil
heel
shigella
invas
process
wild
type
flexneri
strain
serotyp
plasmidless
noninvas
deriv
noninvas
mutant
lp
mutant
lack
copi
msbb
gene
encod
enzym
myristolyl
transferas
carri
hypoacyl
lipid
creat
transform
wild
type
strain
tgi
vector
shigella
sonnei
wild
type
strain
describ
rossi
bacteria
routin
grown
trypticas
soy
broth
tsb
bbl
becton
dickinson
co
cockeysvil
md
agar
tsa
tsa
contain
mg
congo
red
dye
cr
per
liter
use
select
virul
clone
shigella
streptomycin
sm
ampicillin
ap
ad
cultur
bind
assay
pseudomona
aeruginosa
wild
type
laboratori
strain
use
posit
control
procedur
carri
origin
describ
minor
modif
total
cfu
incub
hbss
hank
balanc
salt
solut
bsa
biotinyl
biotinyl
bsa
h
room
temperatur
sampl
extens
wash
hbss
sampl
incub
hbss
bsa
streptavidinfitc
antimous
ig
bd
pharmingen
bind
evalu
fluorescenceactiv
cell
sort
fac
normal
human
serum
nh
produc
buffi
coat
obtain
blood
bank
sapienza
univers
collect
healthi
adult
volunt
blood
donor
histori
shigellosi
follow
written
inform
consent
blood
allow
clot
serum
subsequ
harvest
pool
store
use
heatinactiv
serum
gener
incub
nh
h
exponenti
phase
bacteria
suspend
dulbecco
phosphatebuff
salin
dpb
incub
min
presenc
nh
bacteri
surviv
calcul
cfu
presenc
nhscfu
presenc
x
hela
cell
atcc
cell
biolog
collect
seed
plate
x
cellsml
allow
adher
h
amount
cfu
wild
type
earli
exponenti
phase
incub
either
dmem
gibco
life
technolog
antiipad
ab
bsa
bsa
time
h
use
infect
hela
cell
moi
min
cell
wash
three
time
pb
incub
addit
h
cell
wash
three
time
pb
detach
trypsin
count
lyse
deoxychol
acid
cell
lysat
plate
congo
red
contain
tsb
agar
plate
cfu
count
h
incub
femal
mice
charl
river
calco
itali
maintain
specif
pathogenfre
anim
facil
univers
camerino
euthan
cervic
disloc
trif
kind
gift
maria
rescigno
ifomieo
campu
milan
itali
francesca
granucci
trif
degli
studi
di
milanobicocca
milan
itali
gener
describ
wildtyp
mutant
bmdm
bmdc
deriv
bone
marrow
cell
collect
fiveweekold
femal
mice
alreadi
report
detail
follow
bmdc
bone
barrow
deriv
dendrit
cell
differenti
day
rpmi
lonza
itali
contain
heat
inactiv
fetal
bovin
serum
fb
gibco
life
technolog
nonessenti
amino
acid
uml
penicillin
uml
streptomycin
lonza
itali
supplement
contain
fibroblast
produc
gmcsf
describ
day
bmdc
character
immunostain
mhcii
monoclon
antibodi
bd
pharmingen
itali
flow
cytometr
analysi
facscalibur
cytomet
becton
dickinson
san
ca
usa
data
acquisit
event
sampl
perform
use
cellquest
softwar
becton
dickinson
san
ca
usa
analysi
perform
flowjo
softwar
treestar
inc
ashland
usa
bmdc
infect
flexneri
strain
sonnei
carri
moi
infect
bmdc
incub
h
wash
ad
gentamicin
gibco
cell
incub
h
h
h
h
post
infect
pi
supernat
collect
analyz
releas
indic
cytochalasin
ad
h
infect
invivogen
altern
bacteria
kill
gentamicin
treatment
h
ad
bmdc
moi
supernat
collect
elisa
differ
time
point
h
h
h
h
lp
stimul
bmdc
cell
seed
plate
x
cellswel
lp
stimul
carri
lp
deriv
intracellular
shigella
ilp
shigella
grown
tsb
medium
alp
lp
describ
commerci
e
coli
lp
lp
invivogen
concentr
ngml
h
supernat
collect
elisa
analysi
bmdm
bone
barrow
deriv
macrophag
differenti
day
rpmi
lonza
itali
contain
heat
inactiv
fb
nonessenti
amino
acid
mm
sodium
pyruv
uml
penicillin
uml
streptomycin
lonza
itali
supplement
fibroblast
supernat
contain
mcsf
macrophagecoloni
stimul
factor
doubleposit
cell
consid
differenti
bmdm
use
experi
stimul
assay
differenti
bmdm
seed
plate
x
cellswel
expos
differ
concentr
ngml
ilp
alp
lp
describ
commerci
e
coli
lp
lp
invivogen
stimul
carri
h
h
cell
supernat
recov
store
use
elisa
assay
bmdm
infect
assay
flexneri
sonnei
strain
perform
report
minim
differ
briefli
bacteria
use
moi
cell
pretreat
h
shigella
ilp
alp
lp
e
coli
lp
concentr
ngml
infect
bmdm
incub
h
wash
twice
pb
treat
gentamicin
h
time
supernat
analyz
releas
pbmc
peripher
blood
mononuclear
cell
isol
buffi
coat
obtain
blood
bank
sapienza
univers
healthi
adult
volunt
blood
donor
follow
written
inform
consent
pbmc
peripher
blood
mononuclear
cell
obtain
blood
healthi
adult
volunt
blood
donor
densiti
gradient
monocyt
isol
use
mac
microbead
system
miltenyi
biotec
bergisch
gladbach
germani
monocyt
cultur
day
rpmi
lonza
supplement
heatinactiv
fb
euroclon
fetal
bovin
serum
ge
healthcar
life
scienc
us
nonessenti
amino
acid
mm
sodium
pyruv
uml
penicillin
uml
streptomycin
lonza
itali
ngml
gmcsf
granulocytemacrophag
colonystimul
factor
miltenyi
biotec
obtain
human
macrophag
stimul
assay
mom
peripher
blood
monocytederiv
macrophag
seed
plate
x
cellswel
expos
ngml
lp
deriv
intracellular
shigella
ilp
shigella
grown
tsb
medium
alp
shigella
lp
commerci
e
coli
lp
lp
invivogen
incub
h
cell
supernat
recov
process
elisa
mom
infect
assay
shigella
strain
deriv
strain
sonnei
strain
perform
use
moi
cell
pretreat
shigella
ilp
alp
lp
commerci
e
coli
lp
lp
invivogen
h
ngml
infect
macrophag
incub
h
wash
twice
pb
solut
treat
gentamicin
h
supernat
recov
evalu
elisa
infect
treat
bacteria
shigella
incub
bsa
polyclon
rabbit
antiipad
antibodi
gift
abdel
allaoui
h
moi
use
h
modc
infect
bacteria
moi
mom
death
evalu
opson
recombin
bsa
antiipad
ab
noth
h
room
temperatur
use
infect
mom
moi
h
evalu
lactat
dehydrogenas
ldh
releas
supernat
ldh
measur
cytotox
nonradioact
cytotox
assay
kit
promega
usa
accord
manufacur
instruct
adjust
spontan
lysi
releas
calcul
follow
releas
noninfect
cell
maximum
noninfect
cell
phagocytosi
assay
percentag
bacteri
intern
mom
evalu
cytofluorimetr
analysi
use
mom
marker
cell
posit
gfp
consid
infect
cell
data
acquisit
event
sampl
perform
use
cellquest
softwar
becton
dickinson
san
ca
usa
analysi
perform
flowjo
softwar
treestar
inc
ashland
usa
dendrit
cell
modc
peripher
blood
monocytederiv
dendrit
cell
cultur
stimul
infect
pbmc
obtain
blood
healthi
adult
volunt
blood
donor
densiti
gradient
monocyt
isol
use
mac
microbead
system
miltenyi
biotec
bergisch
gladbach
germani
monocyt
cultur
day
rpmi
lonza
supplement
heatinactiv
fb
hyclon
fetal
bovin
serum
ge
healthcar
life
scienc
us
nonessenti
amino
acid
uml
penicillin
uml
streptomycin
lonza
itali
ngml
ngml
gmcsf
miltenyi
biotec
obtain
immatur
human
dendrit
cell
modc
character
immunostain
bd
pharmingen
itali
flow
cytometr
analysi
modc
stimul
modc
collect
seed
plate
x
cellswel
expos
ngml
ilp
alp
lp
e
coli
lp
h
modc
infect
cell
seed
x
cellswel
morn
infect
exponenti
phase
bacteria
ad
moi
directli
well
contain
modc
plate
centrifug
min
x
g
incub
c
h
fresh
medium
contain
gentamycin
ad
cell
incub
h
h
h
h
fiveweekold
gr
femal
wild
type
charl
river
calco
itali
mice
maintain
specif
pathogenfre
anim
facil
univers
camerino
infect
mice
anesthet
intramuscularli
solut
contain
zoletil
mg
virbac
carro
franc
xilor
bio
san
lazzaro
itali
inocul
intranas
nacl
suspens
contain
x
cfu
flexneri
strain
requir
infect
mice
wild
type
treat
per
day
day
recombin
intraperiton
mgkg
correspond
steril
salin
examin
daili
evalu
surviv
day
n
n
treatedmic
n
noninfect
mice
three
separ
experi
euthan
day
postinfect
n
n
treatedmic
n
noninfect
mice
three
separ
experi
time
bronchoalveolar
lavag
bal
perform
bal
use
cytokin
analysi
lung
remov
homogen
plate
tsa
plate
lung
per
mice
analyz
relev
cytokin
altern
fix
formalin
consecut
section
middl
five
lung
lobe
use
histolog
immunohistochem
examin
experi
use
mice
surviv
analyz
day
pi
n
three
separ
experi
lung
process
assess
bacteri
load
cytokin
product
h
pi
n
mice
n
wild
type
three
separ
experi
lung
sampl
fix
formaldehyd
h
room
temperatur
treat
histopatholog
immunochemistri
studi
describ
sampl
gradual
dehydr
embed
paraffin
specimen
cut
slice
stain
hematoxylineosin
carlo
erba
immunostain
immunohistochemistri
perform
use
follow
antibodi
rabbit
polyclon
antihuman
mous
monoclon
antipmn
clone
thermofish
scientif
usa
section
incub
secondari
antibodi
minut
examin
blindli
score
pathologist
cytokin
chemokin
concentr
determin
commerci
avail
elisa
kit
duo
set
r
system
absorb
measur
micropl
reader
labtech
hercul
ca
usa
lpss
use
studi
use
paciello
refer
articl
relev
inform
experiment
procedur
lp
extract
purif
patient
acut
stage
day
onset
cultureproven
sonnei
shigellosi
recruit
studi
includ
children
age
year
one
adult
control
group
includ
healthi
subject
adult
children
age
year
sign
inform
consent
obtain
parent
particip
children
particip
adult
particip
parent
complet
questionnair
person
data
detail
regard
symptom
onset
diseas
blood
sampl
collect
use
edta
tube
geiner
bioon
plasma
separ
store
oc
assay
data
present
mean
sd
number
independ
experi
indic
legend
figur
statist
perform
graphpad
prism
data
analysi
carri
follow
mantelcox
test
use
compar
surviv
curv
nonparametr
mannwhitney
u
test
cfu
count
cytokinechemokin
quantif
mice
student
ttest
releas
cell
cultur
pair
ttest
quantif
plasma
patient
p
consid
signific
mice
experi
conduct
accord
ethic
requir
anim
care
committe
univers
camerino
studi
protocol
upon
approv
ministero
della
salut
direzion
general
della
animal
e
dei
farmaci
veterinari
ufficio
vi
benesser
animal
line
guidelin
laid
european
commun
council
care
use
laboratori
anim
studi
involv
shigellosi
patient
control
approv
irb
hillel
yaff
medic
center
israel
ministri
health
studi
protocol
written
sign
inform
consent
obtain
parent
particip
children
particip
adult
pbmc
peripher
blood
mononuclear
cell
isol
buffi
coat
obtain
blood
bank
sapienza
univers
healthi
adult
volunt
blood
donor
follow
written
inform
consent
